Alan Remaley, M.D., Ph.D.
Section Chief, Lipoprotein Metabolism Laboratory
National Heart, Lung & Blood Institute (NHLBI), National Institutes of Health (NIH)
“ApoC-II Mimetic Peptides for the Treatment of Hypertriglyceridemia”
Hypertriglyceridemia has long been suspected to be involved in the pathogenesis of atherosclerosis but only has recently been confirmed to be positively linked to cardiovascular disease in large genetic studies. As a consequence, there is limited therapeutic options that have shown to have a positive impact in reducing disease in human clinical trials. Fish oils are approved for lowering triglycerides in patients with extremely elevated triglycerides mostly for the prevention of pancreatitis. Recently, fish oils have also been shown to reduce cardiovascular events on top of statins in patients with only modest increases in triglycerides. In this seminar, triglyceride metabolism and how it relates to atherosclerosis will be reviewed. In addition, a novel apoC‐II mimetic peptide will be presented that activates Lipoprotein Lipase, the main plasma enzyme that hydrolyzes triglycerides. The peptide also acts by displacing apoC‐III, an inhibitor of Lipoprotein Lipase, from the surface of lipoprotein particles. The effect of the peptide treatment on a large variety of animal models of hypertriglyceridemia will be shown along with ex vivo studies on human plasma.
Friday, December 7, 2018, 11:00AM-12:00PM, LIB-110
University of North Texas Health Science Center
Fort Worth, Texas